Affiliations 

  • 1 Department of Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland
  • 2 World Health Organization, Lao People's Democratic Republic, 125 Saphanthong Road, Unit5, Ban Saphanthongtai, Sisattanak District, P.O.Box 343, Vientiane Capital, Lao People's Democratic Republic
  • 3 Quanticlear Solutions Sdn. Bhd, Kuala Lumpur, Malaysia
  • 4 Mother and Child Health Center, National Immunization Programme, Ministry of Health, Vientiane Capital, Lao People's Democratic Republic
  • 5 Department of Health Governance and Financing, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland
  • 6 United Nations Children's Fund, 3 UN Plaza, New York, NY, 10017, USA
  • 7 Department of Immunization, Vaccines and Biologicals, World Health Organization, 20, Avenue Appia, 1211, Geneva 27, Switzerland. [email protected]
BMC Med, 2023 Jul 10;21(1):248.
PMID: 37424001 DOI: 10.1186/s12916-023-02944-1

Abstract

BACKGROUND: The COVID-19 Vaccine Introduction and deployment Costing (CVIC) tool was developed to assist countries to estimate incremental financial costs to roll out COVID-19 vaccines. This article describes the purposes, assumptions and methods used in the CVIC tool and presents the estimated financial costs of delivering COVID-19 vaccines in the Lao People's Democratic Republic (Lao PDR).

METHODS: From March to September 2021, a multidisciplinary team in Lao PDR was involved in the costing exercise of the National Deployment and Vaccination Plan for COVID-19 vaccines to develop potential scenarios and gather inputs using the CVIC tool. Financial costs of introducing COVID-19 vaccines for 3 years from 2021 to 2023 were projected from the government perspective. All costs were collected in 2021 Lao Kip and presented in United States dollar.

RESULTS: From 2021 to 2023, the financial cost required to vaccinate all adults in Lao PDR with primary series of COVID-19 vaccines (1 dose for Ad26.COV2.S (recombinant) vaccine and 2 doses for the other vaccine products) is estimated to be US$6.44 million (excluding vaccine costs) and additionally US$1.44 million and US$1.62 million to include teenagers and children, respectively. These translate to financial costs of US$0.79-0.81 per dose, which decrease to US$0.6 when two boosters are introduced to the population. Capital and operational cold-chain costs contributed 15-34% and 15-24% of the total costs in all scenarios, respectively. 17-26% went to data management, monitoring and evaluation, and oversight, and 13-22% to vaccine delivery.

CONCLUSIONS: With the CVIC tool, costs of five scenarios were estimated with different target population and booster dose use. These facilitated Lao PDR to refine their strategic planning for COVID-19 vaccine rollout and to decide on the level of external resources needed to mobilize and support outreach services. The results may further inform inputs in cost-effectiveness or cost-benefit analyses and potentially be applied and adjusted in similar low- and middle-income settings.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.